|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
Public Release: 23-May-2013
 Cancer ResearchMayo Clinic genomic analysis lends insight to prostate cancer Mayo Clinic researchers have used next generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings appear online today in the journal Cancer Research. 
Waterman Biomarker Discovery
Contact: Bob Nellis
Public Release: 21-May-2013
Journal of the American Chemical SocietyUCI chemists devise inexpensive, accurate way to detect prostate cancer Early screening for prostate cancer could become as easy for men as personal pregnancy testing is for women, thanks to UC Irvine research published today in the Journal of the American Chemical Society. Contact: Janet Wilson
Public Release: 21-May-2013
Cancer DiscoveryChanging cancer's environment to halt its spread By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces metastatic spread in mouse models of prostate, breast and lung cancer. The findings suggest that a prosaposin-based drug could potentially block metastasis in a variety of cancers.
NIH/National Cancer Institute, Norwegian Cancer Society, Norwegian Research Council, and others
Contact: Keri Stedman
Public Release: 20-May-2013
JAMA Internal Medicine2 radiotherapy treatments show similar morbidity, cancer control after prostatectomy Use of the newer, more expensive intensity-modulated radiotherapy and use of the older conformal radiotherapy after surgical removal of all or part of the prostate gland were associated with similar morbidity and cancer control outcomes, according to a study published Online First by JAMA Internal Medicine, a JAMA Network publication. Contact: William Davis
Public Release: 20-May-2013
Annals of Internal MedicineOlder prostate cancer patients should think twice before undergoing treatment Older prostate cancer patients with other underlying health conditions should think twice before committing to surgery or radiation therapy for their cancer.
Robert Wood Johnson VA Clinical Scholars Program, American Urological Association Urology Care Foundation
Contact: Kim Irwin
Public Release: 20-May-2013
JAMA Internal MedicineIMRT may not be more effective than older radiation techniques after prostatectomy Intensity-modulated radiation therapy has become the most commonly used type of radiation in prostate cancer, but research from the University of North Carolina School of Medicine suggests that the therapy may not be more effective than older, less expensive forms of radiation therapy in patients who have had a prostatectomy. Contact: William Davis
Public Release: 20-May-2013
Annals of Internal MedicineEmbargoed news from Annals of Internal Medicine Below is information about articles being published in the May 21 issue of Annals of Internal Medicine. The information is not intended to substitute for the full articles as a source of information. Annals of Internal Medicine attribution is required for all coverage. Contact: Megan Hanks
Public Release: 15-May-2013
2013 ASCO Annual MeetingPARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers from the Perelman School of Medicine at the University of Pennsylvania, will be presented during the American Society of Clinical Oncology's annual meeting in Chicago in early June. Contact: Holly Auer
Public Release: 14-May-2013
CancerComorbidities should be factor in prostate biopsy choice, UCI study finds UC Irvine Health urologists and health policy experts report in a new study that two written assessments that identify existing comorbidities -- the patient-reported Total Illness Burden Index for Prostate Cancer and the physician-reported Charlson Comorbidity Index -- can successfully target prostate patients who would not benefit from biopsy to discover possible cancer. Contact: Tom Vasich
Public Release: 14-May-2013
Journal of General Internal MedicinePrimary care physicians vital to complete care of prostate cancer patients Androgen deprivation therapy is a common and effective treatment for advanced prostate cancer. Among other side-effects, it can cause bone thinning in men on long-term treatment. However, a new study finds that testing is not routine. The authors noted that men were more likely to be tested when they were being cared for by both a urologist and a primary care physician. Their paper appears in the Journal of General Internal Medicine, published by Springer.
NIH/National Cancer Institute, American Cancer Society
Contact: Joan Robinson
Public Release: 13-May-2013
CancerAgent Orange exposure linked to life-threatening prostate cancer A new analysis has found a link between exposure to Agent Orange and lethal forms of prostate cancer among US Veterans. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest that Agent Orange exposure history should be incorporated into prostate screening decisions for Veterans. Contact: Amy Molnar
Public Release: 8-May-2013
Cancer Prevention ResearchSoy and tomato combo may be effective in preventing prostate cancer Tomatoes and soy foods may be more effective in preventing prostate cancer when they are eaten together than when either is eaten alone, said a University of Illinois study. "We used mice that were genetically engineered to develop an aggressive form of prostate cancer. Even so, half the animals that had consumed tomato and soy had no cancerous lesions in the prostate at study's end," said John Erdman, a U of I professor of nutrition.
NIH/National Cancer Institute, National Institutes of Health
Contact: Phyllis Picklesimer
Public Release: 8-May-2013
AUA Annual Meeting 2013New prostate cancer test improves risk assessment A new genomic test for prostate cancer can help predict whether men are more likely to harbor an aggressive form of the disease, according to a new UC San Francisco study. The test, which improves risk assessment when patients are first diagnosed, can also aid in determining which men are suitable for active surveillance -- a way of managing the disease without direct treatment. Contact: Elizabeth Fernandez
Public Release: 7-May-2013
American Journal of PathologyAmplification of a Stat5 gene produces excess oncogenic protein that drives prostate cancer spread An international group of investigators, led by researchers at Thomas Jefferson University's Kimmel Cancer Center, have solved the mystery of why a substantial percentage of castrate-resistant metastatic prostate cancer cells contain abnormally high levels of the pro-growth protein Stat5. Contact: Jackie Kozloski
Public Release: 7-May-2013
AUA Annual Meeting 2013 International Journal of Radiation Oncology*Biology*PhysicsASTRO and AUA issue joint guideline for radiation therapy after prostatectomy The American Society for Radiation Oncology and the American Urological Association are pleased to announce the publication of the joint guideline on radiation therapy after prostatectomy for patients with and without evidence of prostate cancer recurrence. Contact: Michelle Kirkwood
Public Release: 7-May-2013
Cancer Epidemiology, Biomarkers & PreventionSleep problems may increase risk for prostate cancer Problems falling asleep and staying asleep increased the risk for prostate cancer. The association was stronger for advanced disease. Larger studies with longer follow-up are necessary for confirmation. Contact: Jeremy Moore
Public Release: 5-May-2013
AUA Annual Meeting 2013Some prostate cancer patients more likely to die after weekend ER visits Patients with prostate cancer that has metastasized, or spread, to other parts of the body face a significantly higher risk of dying when visiting a hospital emergency department on the weekend instead of on a weekday, according to researchers at Henry Ford Hospital in Detroit. Contact: Dwight Angell
Public Release: 5-May-2013
AUA Annual Meeting 2013Hospital surgical volume should be considered when judging value of procedures The volume of cases performed at an institution each year has a direct effect on the outcome of surgical procedures, and should always be considered when looking at the benefits of a technique, according to a team of researchers at Henry Ford Hospital in Detroit.
Vattikuti Urology Institute
Contact: Dwight Angell
Public Release: 1-May-2013
The ProstateTaking cholesterol-lowering drugs may also reduce the risk of dying from prostate cancer: Study Men with prostate cancer who take cholesterol-lowering drugs called statins are significantly less likely to die from their cancer than men who don't take such medication, according to study led by researchers at Fred Hutchinson Cancer Research Center. The findings are published online today in The Prostate.
NIH/National Cancer Institute, Dutch Cancer Society, Prostate Cancer Foundation, Fred Hutchinson Cancer Research Center
Contact: Kristen Woodward
Public Release: 1-May-2013
Nature MedicineStudy finds key protein for firing up central nervous system inflammation Scientists have identified an influential link in a chain of events that leads to autoimmune inflammation of the central nervous system in a mouse model of multiple sclerosis. Contact: Scott Merville
Public Release: 1-May-2013
AUA Annual Meeting 2013Ferring to present safety analysis for FIRMAGON® (degarelix) at the AUA Annual Meeting A safety analysis for FIRMAGON® (degarelix) will be presented at the annual meeting of the American Urology Association in San Diego, CA.
Ferring Pharmaceuticals
Contact: Molly Wilson
Public Release: 29-Apr-2013
BMC Radiation OncologyVEGF may not be relevant biomarker for advanced prostate cancer The well-studied protein VEGF does not appear to have any prognostic or predictive value for men with locally advanced prostate cancer, researchers from the Department of Radiation Oncology at Thomas Jefferson University Hospital and other institutions found in a retrospective study published online April 25 in the journal BMC Radiation Oncology. Contact: Danielle Servetnick
Public Release: 25-Apr-2013
CellPeriodic bursts of genetic mutations drive prostate cancer Cancer is typically thought to develop after genes gradually mutate over time, finally overwhelming the ability of a cell to control growth. But a new closer look at genomes in prostate cancer by an international team of researchers reveals that, in fact, genetic mutations occur in abrupt, periodic bursts, causing complex, large scale reshuffling of DNA driving the development of prostate cancer. Contact: Lauren Woods
Public Release: 24-Apr-2013
The Journal of UrologyPersonalizing prostate cancer screenings With the help of genetics, prostate specific antigen screenings may become more accurate and reduce the number of unnecessary prostate biopsies, according to a new study from Northwestern Medicine®.
Urological Research Foundation, Prostate SPORE Grant
Contact: Erin White
Public Release: 23-Apr-2013
Cancer Epidemiology, Biomarkers & PreventionObese men with benign biopsy at high risk for prostate cancer Obese men were more likely to have precancerous lesions detected in their benign prostate biopsies compared with nonobese men and were at a greater risk for subsequently developing prostate cancer, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. Contact: Jeremy Moore
|
|
|
||||
|
|
 |
|
